OCREVUS™ (OCRELIZUMAB)

Policy Number: 2019D0056F  Effective Date: April 1, 2019

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVERAGE RATIONALE</td>
<td>1</td>
</tr>
<tr>
<td>U.S. FOOD AND DRUG ADMINISTRATION</td>
<td>2</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>2</td>
</tr>
<tr>
<td>APPLICABLE CODES</td>
<td>2</td>
</tr>
<tr>
<td>BENEFIT CONSIDERATIONS</td>
<td>2</td>
</tr>
<tr>
<td>CLINICAL EVIDENCE</td>
<td>3</td>
</tr>
<tr>
<td>CENTERS FOR MEDICARE AND MEDICAID SERVICES</td>
<td>4</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>4</td>
</tr>
<tr>
<td>POLICY HISTORY/REVISION INFORMATION</td>
<td>5</td>
</tr>
<tr>
<td>INSTRUCTIONS FOR USE</td>
<td>5</td>
</tr>
</tbody>
</table>

COVERAGE RATIONALE

Ocrevus (ocrelizumab) is proven for:

I. Primary Progressive Multiple Sclerosis

Ocrevus is medically necessary for the treatment of primary progressive multiple sclerosis (PPMS) when ALL of the following criteria are met:

A. Diagnosis of primary progressive multiple sclerosis (PPMS); and

B. One of the following:
   1. Initial therapy for ocrelizumab when meeting both of the following:
      a. Patient is not receiving ocrelizumab in combination with any of the following:
         i. Disease modifying therapy (e.g., interferon beta preparations, daclizumab, dimethyl fumarate, glatiramer acetate, natalizumab, fingolimod, or teriflunomide)
         ii. B cell targeted therapy (e.g., rituximab, belimumab, ofatumumab)
         iii. Lymphocyte trafficking blockers (e.g., alemtuzumab, mitoxantrone) and
      b. Initial dosing: One time 300 mg intravenous course of doses on days 1 and 15; and
      c. Initial authorization is for no more than 6 months or
   2. Continuation therapy for ocrelizumab when meeting all of the following:
      a. Patient has previously received treatment with ocrelizumab; and
      b. Documentation of positive clinical response to ocrelizumab therapy; and
      c. Patient is not receiving ocrelizumab in combination with any of the following:
         i. Disease modifying therapy (e.g., interferon beta preparations, daclizumab, dimethyl fumarate, glatiramer acetate, natalizumab, fingolimod, or teriflunomide)
         ii. B cell targeted therapy (e.g., rituximab, belimumab, ofatumumab)
         iii. Lymphocyte trafficking blockers (e.g., alemtuzumab, mitoxantrone) and
      d. Continued dosing: One 600 mg intravenous dose every 6 months; and
      e. Authorization is for no more than 12 months

II. Relapsing Forms of Multiple Sclerosis

Ocrevus is medically necessary for the treatment of relapsing forms of multiple sclerosis (MS) when BOTH of the following criteria are met:

A. Diagnosis of relapsing forms of multiple sclerosis (MS) (e.g., relapsing-remitting MS, secondary-progressive MS with relapses, progressive-relapsing MS with relapses); and
B. **One** of the following:
   1. **Initial therapy for ocrelizumab** meeting all of the following:
      a. Patient is **not** receiving ocrelizumab in combination with **any** of the following:
         i. Disease modifying therapy (e.g., interferon beta preparations, daclizumab, glatiramer acetate, natalizumab, fingolimod, or teriflunomide)
         ii. B cell targeted therapy (e.g., rituximab, belimumab, ofatumumab)
         iii. Lymphocyte trafficking blockers (e.g., alemtuzumab, mitoxantrone) **and**
      b. Initial dosing: One time 300 mg intravenous course of doses on days 1 and 15; **and**
      c. Initial authorization is for no more than 6 months **or**
   2. **Continuation therapy for ocrelizumab** when meeting all of the following:
      a. Patient has previously received treatment with ocrelizumab; **and**
      b. Documentation of positive clinical response to ocrelizumab therapy; **and**
      c. Patient is **not** receiving ocrelizumab in combination with **any** of the following:
         i. Disease modifying therapy (e.g., interferon beta preparations, daclizumab, dimethyl fumarate, glatiramer acetate, natalizumab, fingolimod, or teriflunomide)
         ii. B cell targeted therapy (e.g., rituximab, belimumab, ofatumumab)
         iii. Lymphocyte trafficking blockers (e.g., alemtuzumab, mitoxantrone) **and**
      d. Continued dosing: One 600 mg intravenous dose every 6 months; **and**
      e. Authorization is for no more than 12 months

**Ocrevus is unproven and not medically necessary for the treatment of:**
- Lupus nephritis
- Rheumatoid arthritis
- Systemic lupus erythematosus

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

**Ocrevus is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.**

**BACKGROUND**

Ocrelizumab is a humanized monoclonal antibody designed to selectively target CD20-positive B cells. CD20-positive B cells are a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage, which can result in disability in people with multiple sclerosis. Ocrelizumab binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, and therefore important functions of the immune system may be preserved.

**APPLICABLE CODES**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J2350</td>
<td>Injection, ocrelizumab, 1 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10 Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G35</td>
<td>Multiple sclerosis</td>
</tr>
</tbody>
</table>

**BENEFIT CONSIDERATIONS**

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy. Benefit coverage for an otherwise
unproven service for the treatment of serious rare diseases may occur when certain conditions are met. See the Policy and Procedure addressing the treatment of serious rare diseases.

**CLINICAL EVIDENCE**

**Proven**

**Primary Progressive Multiple Sclerosis (PPMS)**

The Phase 3 ORATORIO study was a multicenter, randomized, double-blind, placebo-controlled, global study evaluating the efficacy and safety of ocrelizumab in patients with primary progressive multiple sclerosis. A total of 732 patients were randomized to receive ocrelizumab 600 mg IV or placebo every 24 weeks. ORATORIO met its primary endpoint, showing treatment with ocrelizumab significantly reduced the risk of 12-week confirmed disability progression (as measured by the Expanded Disability Status Scale) by 24% compared with placebo (p=0.0321). Ocrelizumab also significantly reduced the risk of 24-week confirmed disability progression by 25% vs placebo (p=0.0365). Overall, the incidence of adverse events was similar between ocrelizumab and placebo. The most common adverse events were mild-to-moderate infusion-related reactions. The incidence of serious adverse events, including serious infections, was also similar between ocrelizumab and placebo. In a subgroup analysis of the ORATORIO study, the efficacy of ocrelizumab vs placebo in patients with and without T1 gadolinium-enhancing lesions at baseline was consistent with that in the overall study population. However, the ORATORIO study was not powered to demonstrate efficacy differences between these subgroups. The authors concluded that among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo. Extended observation is required to determine the long-term safety and efficacy of ocrelizumab.

**Relapsing Forms of Multiple Sclerosis (RMS)**

The Phase 3 OPERA I and OPERA II studies were randomized, double-blind, double-dummy, parallel-group studies evaluating the efficacy and safety of ocrelizumab 600 mg every 24 weeks vs interferon beta-1a 44 mcg three times weekly, in patients with relapsing forms of multiple sclerosis. Relapsing forms of multiple sclerosis include patients with relapsing-remitting multiple sclerosis or those with secondary progressive multiple sclerosis who continued to experience relapses. Both the OPERA I and OPERA II studies met their primary and major secondary endpoints. Treatment with ocrelizumab significantly reduced the protocol-defined annualized relapse rate at 96 weeks vs interferon beta-1a by 46% in OPERA I (p<0.0001) and by 47% in OPERA II (p<0.0001). In a pooled analysis of OPERA I and II, ocrelizumab treatment also significantly reduced the time to onset of both 12-week and 24-week confirmed disability progression vs interferon beta-1a by 40% for both time points (p=0.0006 and p=0.0025, respectively). The incidence of adverse events and serious adverse events, including serious infections, was similar between ocrelizumab and interferon beta-1a in both studies. The most common adverse events were mild-to-moderate infusion-related reactions. The authors concluded that among patients with relapsing multiple sclerosis, ocrelizumab was associated with lower rates of disease activity and progression than interferon beta-1a over a period of 96 weeks. Larger and longer studies of the safety of ocrelizumab are required.

**Unproven**

**Lupus Nephritis**

Mysler et al. conducted a Phase 3, randomized, double-blind, placebo-controlled, parallel-group trial (BELONG), to evaluate the safety and efficacy of ocrelizumab in patients with active, proliferative Class 3/4 lupus nephritis. Patients were randomized to receive placebo, ocrelizumab 400 mg or ocrelizumab 1,000 mg IV on Days 1 and 15, followed by a single infusion at Week 16 and every 16 weeks thereafter. All patients received standard of care (mycophenolate mofetil or cyclophosphamide followed by azathioprine) and were also permitted to receive IV or oral steroids. The primary endpoint was the ORR (CRR and PRR) at Week 48. Efficacy outcomes at Week 48 were analyzed for patients who were treated for ≥32 weeks prior to study termination (n=223). At Week 48 the ORR rates were 66.7% and 67.1% in the ocrelizumab 400 mg (n=75) and 1,000 mg groups (n=73), respectively, vs 54.7% in the placebo group (n=75). The associated treatment difference vs placebo was 12.1% (95% CI -3.3 to 27.5) for the ocrelizumab 400 mg group and 13.9% (95% CI -1.4 to 29.2) for the 1,000 mg group. The combined ORR for the 2 ocrelizumab groups was 66.9% with an associated treatment difference of 12.7% (95% CI -0.8 to 26.1) vs placebo. An imbalance in the rate of serious and opportunistic infections in ocrelizumab-treated patients led to an early termination of the study. Patients continued into safety follow-up.

**Rheumatoid Arthritis**

Due to the conclusion that the benefit to risk profile was not favorable, the manufacturer of ocrelizumab has discontinued the clinical program for rheumatoid arthritis. The manufacturer has taken into account the currently available treatment options. An infection safety signal was detected which included serious infections, some of which were fatal, and opportunistic infections.

The ocrelizumab clinical studies for RA included 4 Phase 3 studies (STAGE, SCRIPT, FILM, and FEATURE). STAGE (DMARD inadequate response population) and SCRIPT (anti-TNF inadequate response population) were 48-week
randomized, double-blind, placebo-controlled, parallel group studies, followed by an open-label extension period. During the double-blind treatment periods, patients received 2 courses of ocrelizumab at 6-month intervals (each course consisted of 2 infusions of ocrelizumab 200 mg or 500 mg IV on Days 1 and 15 and Weeks 24 and 26). The patients also received traditional DMARD(s) as background therapy.\(^8\)\(^\textit{11}\)

**REFERENCES**

**Manual, Chapter 15, §50**

that the drugs are not usually self-administered by the patients who take them. See the [Medicare Benefit Policy Manual, Chapter 15, §50 - Drugs and Biologicals](https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCov Coverage/Medicare-MedicarePrescriptionDrugCover.html). (Accessed August 23, 2018)

**CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)**

Medicare does not have a National Coverage Determination (NCD) for OCREVUS\(^\text{®}\) (ocrelizumab) used in the treatment of relapsing or primary progressive multiple sclerosis. Local Coverage Determinations (LCDs) do not exist at this time.

In general, Medicare covers outpatient (Part B) drugs that are furnished “incident to” a physician’s service provided that the drugs are not usually self-administered by the patients who take them. See the [Medicare Benefit Policy Manual, Chapter 15, §50 - Drugs and Biologicals](https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCov Coverage/Medicare-MedicarePrescriptionDrugCover.html). (Accessed August 23, 2018)

**Systemic Lupus Erythematosus**

Md Yusof et al. conducted an observational study of 88 patients with SLE who were treated with 2 infusions of rituximab 1,000 mg repeated upon clinical relapse. Patients who had features of HACA were given ocrelizumab 1,000 mg IV x 2 or a rituximab desensitizing regimen.\(^13\) Response was defined as improvement to ≤1 persistent BILAG B and no A/B flare. Of the 76 (86%) primary responders, 63 were retreated with rituximab upon relapse. Of these, 54 continued to respond (median [IQR] time-to-CI-relapse: 54 [37-93] weeks) while 9 were secondary non-responders (median [IQR] time-to-CI-relapse: 62 [47-95] weeks). 8 of the 9 secondary non-responders were due to HACA, 3 of who were treated with ocrelizumab. All 3 patients who were treated with ocrelizumab had a response and complete peripheral B cell depletion. One secondary non-responder was desensitized with rituximab and continued to experience HACA.

**REFERENCES**


16. Ocrevus [prescribing information], South San Francisco, CA; Genentech, Inc. November 2018.

POLICY HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/01/2019</td>
<td>Reorganized policy template; simplified and relocated Instructions for Use and Benefit Considerations section. Policy 2018D0056D archived.</td>
</tr>
</tbody>
</table>
| 01/01/2018 | • Added list of applicable HCPCS codes to reflect annual code edits: J2350  
• Archived previous policy version 2017D0056B |
| 01/01/2017 | New policy 2017D0056A. Approved by National Pharmacy & Therapeutics Committee on 08/19/2016. |

INSTRUCTIONS FOR USE

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard benefit plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Benefit Drug Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. UnitedHealthcare Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.